Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

As science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal time for the HIV response, one defined by both incredible scientific ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...